Pre-mRNA splicing as a target for antisense oligonucleotides
Identifieur interne : 000E82 ( Istex/Corpus ); précédent : 000E81; suivant : 000E83Pre-mRNA splicing as a target for antisense oligonucleotides
Auteurs : Ryszard Kole ; Ram R. Shukla ; Saghir AkhtarSource :
- Advanced Drug Delivery Reviews [ 0169-409X ] ; 1991.
English descriptors
- Teeft :
- Acad, Antisense, Antisense oligonucleotides, Antiviral, Antiviral activity, Biol, Branch point, Branch point sequence, Branch point sequences, Cell membrane, Chapel hill, Cleavage, Cultured cells, Exon, Exon sequences, First step, Form duplexes, Gene expression, Herpes simplex virus type, Human immunodeficiency virus, Immunodeficiency, Intron, Intron sequences, Kole, Large number, Mrna, Natl, Nucleic acids, Nucleotide, Oligonucleotide, Oligonucleotides, Oligonucleotides antisense, Phosphorothioate, Proc, Replication, Ribonucleoprotein, Ribonucleoprotein particle, Ribonucleoprotein particles, Rnase, Snrna, Snrnp, Snrnps, Splice, Splice site, Splice sites, Spliceosome, Viral, Zamecnik.
Abstract
Abstract: Splicing is one of the major post-transcriptional modifications a eukaryotic mRNA precursor (pre-mRNA) has to undergo to yield the mature mRNA. During pre-mRNA splicing the non-coding sequences (introns) of the precursor are removed and coding sequences (exons) are joined. This process takes place within a complex called a spliceosome and requires the presence of a number of splicing factors such as small nuclear ribonucleoprotein particles (snRNPs). Oligonucleotides containing sequences complementary (antisense) to unique sequences within the pre-mRNA can be used to modify splicing and, thus, gene expression. Likewise, snRNPs provide another important target for using antisense oligonucleotides as investigative tools to further study the mechanism of splicing. This article reviews the available literature on the use of antisense oligonucleotides targeted against pre-mRNA and those targeted against small nuclear ribonucleoprotein particles (snRNPs) within the spliceosomal complex.
Url:
DOI: 10.1016/0169-409X(91)90021-4
Links to Exploration step
ISTEX:182C0B5F1611BB8E2B8203EAC9B4DE94CC553472Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Pre-mRNA splicing as a target for antisense oligonucleotides</title><author><name sortKey="Kole, Ryszard" sort="Kole, Ryszard" uniqKey="Kole R" first="Ryszard" last="Kole">Ryszard Kole</name><affiliation><mods:affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Shukla, Ram R" sort="Shukla, Ram R" uniqKey="Shukla R" first="Ram R." last="Shukla">Ram R. Shukla</name><affiliation><mods:affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Akhtar, Saghir" sort="Akhtar, Saghir" uniqKey="Akhtar S" first="Saghir" last="Akhtar">Saghir Akhtar</name><affiliation><mods:affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:182C0B5F1611BB8E2B8203EAC9B4DE94CC553472</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1016/0169-409X(91)90021-4</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-C04RM7G7-7/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000E82</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Pre-mRNA splicing as a target for antisense oligonucleotides</title><author><name sortKey="Kole, Ryszard" sort="Kole, Ryszard" uniqKey="Kole R" first="Ryszard" last="Kole">Ryszard Kole</name><affiliation><mods:affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Shukla, Ram R" sort="Shukla, Ram R" uniqKey="Shukla R" first="Ram R." last="Shukla">Ram R. Shukla</name><affiliation><mods:affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Akhtar, Saghir" sort="Akhtar, Saghir" uniqKey="Akhtar S" first="Saghir" last="Akhtar">Saghir Akhtar</name><affiliation><mods:affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Advanced Drug Delivery Reviews</title><title level="j" type="abbrev">ADR</title><idno type="ISSN">0169-409X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991">1991</date><biblScope unit="volume">6</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="271">271</biblScope><biblScope unit="page" to="286">286</biblScope></imprint><idno type="ISSN">0169-409X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0169-409X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Antisense</term><term>Antisense oligonucleotides</term><term>Antiviral</term><term>Antiviral activity</term><term>Biol</term><term>Branch point</term><term>Branch point sequence</term><term>Branch point sequences</term><term>Cell membrane</term><term>Chapel hill</term><term>Cleavage</term><term>Cultured cells</term><term>Exon</term><term>Exon sequences</term><term>First step</term><term>Form duplexes</term><term>Gene expression</term><term>Herpes simplex virus type</term><term>Human immunodeficiency virus</term><term>Immunodeficiency</term><term>Intron</term><term>Intron sequences</term><term>Kole</term><term>Large number</term><term>Mrna</term><term>Natl</term><term>Nucleic acids</term><term>Nucleotide</term><term>Oligonucleotide</term><term>Oligonucleotides</term><term>Oligonucleotides antisense</term><term>Phosphorothioate</term><term>Proc</term><term>Replication</term><term>Ribonucleoprotein</term><term>Ribonucleoprotein particle</term><term>Ribonucleoprotein particles</term><term>Rnase</term><term>Snrna</term><term>Snrnp</term><term>Snrnps</term><term>Splice</term><term>Splice site</term><term>Splice sites</term><term>Spliceosome</term><term>Viral</term><term>Zamecnik</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Splicing is one of the major post-transcriptional modifications a eukaryotic mRNA precursor (pre-mRNA) has to undergo to yield the mature mRNA. During pre-mRNA splicing the non-coding sequences (introns) of the precursor are removed and coding sequences (exons) are joined. This process takes place within a complex called a spliceosome and requires the presence of a number of splicing factors such as small nuclear ribonucleoprotein particles (snRNPs). Oligonucleotides containing sequences complementary (antisense) to unique sequences within the pre-mRNA can be used to modify splicing and, thus, gene expression. Likewise, snRNPs provide another important target for using antisense oligonucleotides as investigative tools to further study the mechanism of splicing. This article reviews the available literature on the use of antisense oligonucleotides targeted against pre-mRNA and those targeted against small nuclear ribonucleoprotein particles (snRNPs) within the spliceosomal complex.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>antisense</json:string><json:string>oligonucleotides</json:string><json:string>antisense oligonucleotides</json:string><json:string>snrnps</json:string><json:string>intron</json:string><json:string>splice</json:string><json:string>splice site</json:string><json:string>snrnp</json:string><json:string>rnase</json:string><json:string>exon</json:string><json:string>splice sites</json:string><json:string>oligonucleotide</json:string><json:string>ribonucleoprotein</json:string><json:string>natl</json:string><json:string>snrna</json:string><json:string>acad</json:string><json:string>proc</json:string><json:string>biol</json:string><json:string>kole</json:string><json:string>immunodeficiency</json:string><json:string>branch point</json:string><json:string>spliceosome</json:string><json:string>antiviral</json:string><json:string>ribonucleoprotein particles</json:string><json:string>mrna</json:string><json:string>zamecnik</json:string><json:string>human immunodeficiency virus</json:string><json:string>phosphorothioate</json:string><json:string>viral</json:string><json:string>antiviral activity</json:string><json:string>intron sequences</json:string><json:string>branch point sequences</json:string><json:string>branch point sequence</json:string><json:string>gene expression</json:string><json:string>nucleic acids</json:string><json:string>herpes simplex virus type</json:string><json:string>oligonucleotides antisense</json:string><json:string>nucleotide</json:string><json:string>replication</json:string><json:string>exon sequences</json:string><json:string>chapel hill</json:string><json:string>cultured cells</json:string><json:string>cleavage</json:string><json:string>first step</json:string><json:string>form duplexes</json:string><json:string>cell membrane</json:string><json:string>large number</json:string><json:string>ribonucleoprotein particle</json:string></teeft></keywords><author><json:item><name>Ryszard Kole</name><affiliations><json:string>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</json:string></affiliations></json:item><json:item><name>Ram R. Shukla</name><affiliations><json:string>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</json:string></affiliations></json:item><json:item><name>Saghir Akhtar</name><affiliations><json:string>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>RNA processing</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Spliceosome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Small nuclear ribonucleoprotein particle</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>RNase H</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Deoxyoligonucleotide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Methylphosphonate oligonucleotide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Phosphorothioate oligonucleotide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Gene expression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>snRNP, small nuclear ribonucleoprotein particle</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>D-oligo, deoxyoligonucleotide with normal phosphodiester internucleotide bonds</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>S-oligo, deoxyoligonucleotide with phosphorothioate internucleotide bonds</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MP-oligo, deoxyoligonucleotide with methylphosphonate internucleotide bonds</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HSV-1 (-2), herpes simplex virus type 1(2)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HIV, human immunodeficiency virus</value></json:item></subject><arkIstex>ark:/67375/6H6-C04RM7G7-7</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Review article</json:string></originalGenre><abstract>Abstract: Splicing is one of the major post-transcriptional modifications a eukaryotic mRNA precursor (pre-mRNA) has to undergo to yield the mature mRNA. During pre-mRNA splicing the non-coding sequences (introns) of the precursor are removed and coding sequences (exons) are joined. This process takes place within a complex called a spliceosome and requires the presence of a number of splicing factors such as small nuclear ribonucleoprotein particles (snRNPs). Oligonucleotides containing sequences complementary (antisense) to unique sequences within the pre-mRNA can be used to modify splicing and, thus, gene expression. Likewise, snRNPs provide another important target for using antisense oligonucleotides as investigative tools to further study the mechanism of splicing. This article reviews the available literature on the use of antisense oligonucleotides targeted against pre-mRNA and those targeted against small nuclear ribonucleoprotein particles (snRNPs) within the spliceosomal complex.</abstract><qualityIndicators><score>8.632</score><pdfWordCount>7222</pdfWordCount><pdfCharCount>41277</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>16</pdfPageCount><pdfPageSize>526 x 742 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>136</abstractWordCount><abstractCharCount>1005</abstractCharCount><keywordCount>14</keywordCount></qualityIndicators><title>Pre-mRNA splicing as a target for antisense oligonucleotides</title><pii><json:string>0169-409X(91)90021-4</json:string></pii><genre><json:string>review-article</json:string></genre><serie><title>Transcription and Splicing</title><language><json:string>unknown</json:string></language><pages><first>131</first><last>206</last></pages></serie><host><title>Advanced Drug Delivery Reviews</title><language><json:string>unknown</json:string></language><publicationDate>1991</publicationDate><issn><json:string>0169-409X</json:string></issn><pii><json:string>S0169-409X(00)X0101-9</json:string></pii><volume>6</volume><issue>3</issue><pages><first>271</first><last>286</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1991</json:string></date><geogName></geogName><orgName><json:string>Research Center, School of Medicine, The University of North Carolina</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>I. Introduction</json:string></persName><placeName></placeName><ref_url></ref_url><ref_bibl><json:string>Accepted October 1, 1990</json:string><json:string>Received August 15, 1990</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-C04RM7G7-7</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmaceutical Science</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences biologiques fondamentales et appliquees. psychologie</json:string><json:string>4 - genetique des eucaryotes. evolution biologique et moleculaire</json:string></inist></categories><publicationDate>1991</publicationDate><copyrightDate>1991</copyrightDate><doi><json:string>10.1016/0169-409X(91)90021-4</json:string></doi><id>182C0B5F1611BB8E2B8203EAC9B4DE94CC553472</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-C04RM7G7-7/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-C04RM7G7-7/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-C04RM7G7-7/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Pre-mRNA splicing as a target for antisense oligonucleotides</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1991</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Pre-mRNA splicing as a target for antisense oligonucleotides</title><author xml:id="author-0000"><persName><forename type="first">Ryszard</forename><surname>Kole</surname></persName><note type="correspondence"><p>Correspondence: R. Kole, Lineberger Cancer Research Center, CB 7295, Department of Pharmacology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, U.S.A.</p></note><affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Ram R.</forename><surname>Shukla</surname></persName><affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Saghir</forename><surname>Akhtar</surname></persName><affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</affiliation></author><idno type="istex">182C0B5F1611BB8E2B8203EAC9B4DE94CC553472</idno><idno type="ark">ark:/67375/6H6-C04RM7G7-7</idno><idno type="DOI">10.1016/0169-409X(91)90021-4</idno><idno type="PII">0169-409X(91)90021-4</idno></analytic><monogr><title level="j">Advanced Drug Delivery Reviews</title><title level="j" type="abbrev">ADR</title><idno type="pISSN">0169-409X</idno><idno type="PII">S0169-409X(00)X0101-9</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991"></date><biblScope unit="volume">6</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="271">271</biblScope><biblScope unit="page" to="286">286</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1991</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Splicing is one of the major post-transcriptional modifications a eukaryotic mRNA precursor (pre-mRNA) has to undergo to yield the mature mRNA. During pre-mRNA splicing the non-coding sequences (introns) of the precursor are removed and coding sequences (exons) are joined. This process takes place within a complex called a spliceosome and requires the presence of a number of splicing factors such as small nuclear ribonucleoprotein particles (snRNPs). Oligonucleotides containing sequences complementary (antisense) to unique sequences within the pre-mRNA can be used to modify splicing and, thus, gene expression. Likewise, snRNPs provide another important target for using antisense oligonucleotides as investigative tools to further study the mechanism of splicing. This article reviews the available literature on the use of antisense oligonucleotides targeted against pre-mRNA and those targeted against small nuclear ribonucleoprotein particles (snRNPs) within the spliceosomal complex.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>RNA processing</term></item><item><term>Spliceosome</term></item><item><term>Small nuclear ribonucleoprotein particle</term></item><item><term>RNase H</term></item><item><term>Deoxyoligonucleotide</term></item><item><term>Methylphosphonate oligonucleotide</term></item><item><term>Phosphorothioate oligonucleotide</term></item><item><term>Gene expression</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Abbreviations</head><item><term>snRNP, small nuclear ribonucleoprotein particle</term></item><item><term>D-oligo, deoxyoligonucleotide with normal phosphodiester internucleotide bonds</term></item><item><term>S-oligo, deoxyoligonucleotide with phosphorothioate internucleotide bonds</term></item><item><term>MP-oligo, deoxyoligonucleotide with methylphosphonate internucleotide bonds</term></item><item><term>HSV-1 (-2), herpes simplex virus type 1(2)</term></item><item><term>HIV, human immunodeficiency virus</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1991">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-C04RM7G7-7/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="rev"><item-info><jid>ADR</jid><aid>91900214</aid><ce:pii>0169-409X(91)90021-4</ce:pii><ce:doi>10.1016/0169-409X(91)90021-4</ce:doi><ce:copyright type="unknown" year="1991"></ce:copyright></item-info><head><ce:title>Pre-mRNA splicing as a target for antisense oligonucleotides</ce:title><ce:author-group><ce:author><ce:given-name>Ryszard</ce:given-name><ce:surname>Kole</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Ram R.</ce:given-name><ce:surname>Shukla</ce:surname></ce:author><ce:author><ce:given-name>Saghir</ce:given-name><ce:surname>Akhtar</ce:surname></ce:author><ce:affiliation><ce:textfn>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Correspondence: R. Kole, Lineberger Cancer Research Center, CB 7295, Department of Pharmacology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, U.S.A.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="15" month="8" year="1990"></ce:date-received><ce:date-accepted day="1" month="10" year="1990"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Splicing is one of the major post-transcriptional modifications a eukaryotic mRNA precursor (pre-mRNA) has to undergo to yield the mature mRNA. During pre-mRNA splicing the non-coding sequences (introns) of the precursor are removed and coding sequences (exons) are joined. This process takes place within a complex called a spliceosome and requires the presence of a number of splicing factors such as small nuclear ribonucleoprotein particles (snRNPs). Oligonucleotides containing sequences complementary (antisense) to unique sequences within the pre-mRNA can be used to modify splicing and, thus, gene expression. Likewise, snRNPs provide another important target for using antisense oligonucleotides as investigative tools to further study the mechanism of splicing. This article reviews the available literature on the use of antisense oligonucleotides targeted against pre-mRNA and those targeted against small nuclear ribonucleoprotein particles (snRNPs) within the spliceosomal complex.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>RNA processing</ce:text></ce:keyword><ce:keyword><ce:text>Spliceosome</ce:text></ce:keyword><ce:keyword><ce:text>Small nuclear ribonucleoprotein particle</ce:text></ce:keyword><ce:keyword><ce:text>RNase H</ce:text></ce:keyword><ce:keyword><ce:text>Deoxyoligonucleotide</ce:text></ce:keyword><ce:keyword><ce:text>Methylphosphonate oligonucleotide</ce:text></ce:keyword><ce:keyword><ce:text>Phosphorothioate oligonucleotide</ce:text></ce:keyword><ce:keyword><ce:text>Gene expression</ce:text></ce:keyword></ce:keywords><ce:keywords class="abr"><ce:section-title>Abbreviations</ce:section-title><ce:keyword><ce:text>snRNP, small nuclear ribonucleoprotein particle</ce:text></ce:keyword><ce:keyword><ce:text>D-oligo, deoxyoligonucleotide with normal phosphodiester internucleotide bonds</ce:text></ce:keyword><ce:keyword><ce:text>S-oligo, deoxyoligonucleotide with phosphorothioate internucleotide bonds</ce:text></ce:keyword><ce:keyword><ce:text>MP-oligo, deoxyoligonucleotide with methylphosphonate internucleotide bonds</ce:text></ce:keyword><ce:keyword><ce:text>HSV-1 (-2), herpes simplex virus type 1(2)</ce:text></ce:keyword><ce:keyword><ce:text>HIV, human immunodeficiency virus</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Pre-mRNA splicing as a target for antisense oligonucleotides</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Pre-mRNA splicing as a target for antisense oligonucleotides</title></titleInfo><name type="personal"><namePart type="given">Ryszard</namePart><namePart type="family">Kole</namePart><affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</affiliation><description>Correspondence: R. Kole, Lineberger Cancer Research Center, CB 7295, Department of Pharmacology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ram R.</namePart><namePart type="family">Shukla</namePart><affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Saghir</namePart><namePart type="family">Akhtar</namePart><affiliation>Department of Pharmacology and Lineberger Cancer Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="Review article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1991</dateIssued><copyrightDate encoding="w3cdtf">1991</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Splicing is one of the major post-transcriptional modifications a eukaryotic mRNA precursor (pre-mRNA) has to undergo to yield the mature mRNA. During pre-mRNA splicing the non-coding sequences (introns) of the precursor are removed and coding sequences (exons) are joined. This process takes place within a complex called a spliceosome and requires the presence of a number of splicing factors such as small nuclear ribonucleoprotein particles (snRNPs). Oligonucleotides containing sequences complementary (antisense) to unique sequences within the pre-mRNA can be used to modify splicing and, thus, gene expression. Likewise, snRNPs provide another important target for using antisense oligonucleotides as investigative tools to further study the mechanism of splicing. This article reviews the available literature on the use of antisense oligonucleotides targeted against pre-mRNA and those targeted against small nuclear ribonucleoprotein particles (snRNPs) within the spliceosomal complex.</abstract><subject><genre>Keywords</genre><topic>RNA processing</topic><topic>Spliceosome</topic><topic>Small nuclear ribonucleoprotein particle</topic><topic>RNase H</topic><topic>Deoxyoligonucleotide</topic><topic>Methylphosphonate oligonucleotide</topic><topic>Phosphorothioate oligonucleotide</topic><topic>Gene expression</topic></subject><subject><genre>Abbreviations</genre><topic>snRNP, small nuclear ribonucleoprotein particle</topic><topic>D-oligo, deoxyoligonucleotide with normal phosphodiester internucleotide bonds</topic><topic>S-oligo, deoxyoligonucleotide with phosphorothioate internucleotide bonds</topic><topic>MP-oligo, deoxyoligonucleotide with methylphosphonate internucleotide bonds</topic><topic>HSV-1 (-2), herpes simplex virus type 1(2)</topic><topic>HIV, human immunodeficiency virus</topic></subject><relatedItem type="host"><titleInfo><title>Advanced Drug Delivery Reviews</title></titleInfo><titleInfo type="abbreviated"><title>ADR</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1991</dateIssued></originInfo><identifier type="ISSN">0169-409X</identifier><identifier type="PII">S0169-409X(00)X0101-9</identifier><part><date>1991</date><detail type="issue"><title>Modified Therapeutic Proteins </title></detail><detail type="volume"><number>6</number><caption>vol.</caption></detail><detail type="issue"><number>3</number><caption>no.</caption></detail><extent unit="issue-pages"><start>235</start><end>322</end></extent><extent unit="pages"><start>271</start><end>286</end></extent></part></relatedItem><identifier type="istex">182C0B5F1611BB8E2B8203EAC9B4DE94CC553472</identifier><identifier type="ark">ark:/67375/6H6-C04RM7G7-7</identifier><identifier type="DOI">10.1016/0169-409X(91)90021-4</identifier><identifier type="PII">0169-409X(91)90021-4</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-C04RM7G7-7/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:182C0B5F1611BB8E2B8203EAC9B4DE94CC553472
|texte= Pre-mRNA splicing as a target for antisense oligonucleotides
}}
| This area was generated with Dilib version V0.6.33. |  |